ESMO 2026:
Key Findings for Cancer Care and Drug Development
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
As oncology research continues to advance, understanding the clinical significance of emerging evidence is essential for informing treatment strategies and guiding future research. The European Society for Medical Oncology (ESMO) Congress 2026 brought together healthcare professionals, researchers and industry experts to examine the latest advances in cancer research, treatment and clinical practice.
This webinar will explore key clinical trial results and advances in cancer therapies presented at ESMO 2026, with a focus on their implications for cancer treatment and oncology drug development. By examining these findings alongside existing treatment approaches, the discussion will highlight opportunities to improve patient care and advance therapeutic development.
The featured speakers will place these findings in the context of current evidence, examining their relevance to treatment decisions, remaining uncertainties and priorities for further research. Participants will gain a concise overview of the key messages presented at the congress and their significance for cancer care and oncology development programs.
Register for this webinar to learn how key findings from ESMO 2026 may inform clinical decision-making, cancer treatment strategies and future oncology research.
Who should attend
- Medical/Clinical Oncologists
- Oncology Fellows and Trainees
- Clinical Researchers
- Medical Affairs professionals
- Medical Directors
- Translational Medicine Scientists
- Pharmaceutical and biotechnology R&D professionals
What you will learn
- Key clinical trial findings and emerging oncology research presented at ESMO 2026
- Advances in cancer therapies and their potential implications for clinical practice
- How emerging evidence may inform treatment decisions and future drug development strategies
- Remaining clinical uncertainties, research gaps and priorities shaping the future of cancer care
Featured Speakers
Brandon Fletcher
Dr. Brandon Fletcher is Head of Medical Affairs and Cell & Gene Therapy at Kapadi. She brings more than three decades of drug development experience, with a deep focus on immuno-oncology and cell and gene therapies. Her work spans clinical development strategy, protocol design, scientific and medical oversight, investigator engagement and translating complex biology into executable clinical programs. She was an original collaborator with the NCI’s origination of cancer cell and gene therapeutics and has continued in the field of immuno-oncology and genetically modified cell therapeutics. She co-founded a global philanthropic organization that supports and trains investigators in underserved countries.
Scott E. Smith, MD, PhD, FACP
Scott E. Smith, MD, PhD, FACP, is Chief Medical Officer at Kapadi and a Physician-Scientist with more than 20 years of leadership in hematology, oncology and clinical research. As Senior Vice President and Global Head of Hematology at Parexel, he oversaw global clinical trial operations across more than 20 countries. As Founder and CEO of Chemosabe Consulting, he has advised more than 15 pharmaceutical and biotechnology companies on clinical development and immunotherapy strategy, contributing to the launch of four hematology and oncology therapies.
Previously, Dr. Smith served as Associate Cancer Center Director and Section Chief of Hematology at Loyola University Medical Center, where he expanded clinical programs and led teams of more than 50 professionals. His work includes bone marrow transplantation, CAR T-cell therapy, precision medicine initiatives and review for the FDA Orphan Products Development Program. He has authored more than 150 peer-reviewed publications and abstracts and has spoken at international meetings including ASH and ASCO. Dr. Smith earned his MD and PhD at Wayne State University and is board certified in Internal Medicine, Hematology and Medical Oncology.
Partner for this event
Humaneva Group
Humaneva Group: Revolutionizing Oncology Research by a Fully Integrated Approach
Humaneva Group is an integrated clinical research company that brings together specialized research sites, global CRO capabilities, and advanced clinical technology to improve how clinical trials are planned, conducted, and delivered.
Through its interconnected companies (Pratia, Kapadi, and Hyggio), Humaneva connects patients, investigators, research sites, sponsors, and clinical data within a coordinated operating model designed to increase efficiency, data quality, and certainty of execution.
With a particular focus on oncology, Humaneva Oncology combines an embedded oncology site network, purpose-built CRO expertise, patient identification and screening intelligence, and real-time data capabilities. This integrated approach reduces fragmentation, strengthens accountability, and helps sponsors navigate increasingly complex clinical development programs—from early planning and patient access through trial delivery and reliable data generation.